Redeye embraces another quarter of continuous sales growth and key activities in its clinical trial progressions but notes a lingering uncertainty in COGS and the need for cash. We believe the coming +12 months will offer an opportunity for IRRAS to demonstrate its commercial progress and increase interest among investors once its balance sheet is once again strengthened. We adjust our fair value range based on the assumption of an equity issue in late 2023e.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.